{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:52Z","timestamp":1786119652026,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,1]]},"DOI":"10.1097\/qai.0b013e3182097426","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T03:03:23Z","timestamp":1297393403000},"page":"S7-S13","source":"Crossref","is-referenced-by-count":36,"title":["The BHIVES Collaborative: Organization and Evaluation of a Multisite Demonstration of Integrated Buprenorphine\/Naloxone and HIV Treatment"],"prefix":"10.1097","volume":"56","author":[{"given":"Linda","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Botsko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Netherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Fiellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210131","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.58.5.503","article-title":"A 33-year follow-up of narcotics addicts.","volume":"58","author":"Hser","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"R2-3-20210131","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/070674370605101002","article-title":"Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN).","volume":"51","author":"Fischer","year":"2006","journal-title":"Can J Psychiatry"},{"key":"R3-3-20210131","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1089\/apc.2008.0005","article-title":"Health-related quality of life in HIV-infected patients: the role of substance use.","volume":"22","author":"Korthuis","year":"2008","journal-title":"AIDS Patient Care STDs"},{"key":"R4-3-20210131","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/09595230500286039","article-title":"The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS).","volume":"24","author":"Ross","year":"2005","journal-title":"Drug Alcohol Rev"},{"key":"R5-3-20210131","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/aid.2006.22.715","article-title":"Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.","volume":"22","author":"Rodriguez-Arenas","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R6-3-20210131","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1080\/09540120701351888","article-title":"The impact of illicit drug use and substance abuse treatment on adherence to HAART.","volume":"19","author":"Hicks","year":"2007","journal-title":"AIDS Care"},{"key":"R7-3-20210131","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1468-1293.2008.00582.x","article-title":"Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.","volume":"9","author":"Wood","year":"2008","journal-title":"HIV Med"},{"key":"R8-3-20210131","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/09540120802001705","article-title":"Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders.","volume":"21","author":"Mellins","year":"2009","journal-title":"AIDS Care"},{"key":"R9-3-20210131","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1545109705284353","article-title":"Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use.","volume":"4","author":"Shannon","year":"2005","journal-title":"J Int Assoc Physicians AIDS Care (Chic Ill)"},{"key":"R10-3-20210131","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00126334-200203010-00007","article-title":"HIV-1 RNA viral load monitoring in HIV-infected drug users on antiretroviral therapy: relationship with outpatient care patterns.","volume":"29","author":"Laine","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-3-20210131","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11904-008-0030-4","article-title":"Variations in sexual risks in drug users: emerging themes in a behavioral context.","volume":"5","author":"Celentano","year":"2008","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R12-3-20210131","first-page":"329","article-title":"HIV-associated behaviors among injecting-drug users-23 cities, United States, May 2005-February 2006.","volume":"58","year":"2009","journal-title":"MMWR Morbid Mortal Wkly Rep"},{"key":"R13-3-20210131","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.02.003","article-title":"Antiretroviral adherence and HIV treatment outcomes among HIV\/HCV co-infected injection drug users: the role of methadone maintenance therapy.","volume":"84","author":"Palepu","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"R14-3-20210131","first-page":"347","article-title":"Methadone maintenance treatment (MMT): a review of historical and clinical issues.","volume":"67","author":"Joseph","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"R15-3-20210131","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jurban\/79.4.571","article-title":"Beliefs about methadone in an inner-city methadone clinic.","volume":"79","author":"Stancliff","year":"2002","journal-title":"J Urban Health"},{"key":"R16-3-20210131","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1360-0443.1998.9345157.x","article-title":"The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis.","volume":"93","author":"Marsch","year":"1998","journal-title":"Addiction"},{"key":"R17-3-20210131","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/10550490802268835","article-title":"Attitudes toward buprenorphine and methadone among opioid-dependent individuals.","volume":"17","author":"Schwartz","year":"2008","journal-title":"Am J Addict"},{"key":"R18-3-20210131","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.drugalcdep.2004.12.008","article-title":"The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?","volume":"79","author":"Sullivan","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"R19-3-20210131","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/00952990802122564","article-title":"Pharmacogenetic treatments for drug addiction: alcohol and opiates.","volume":"34","author":"Haile","year":"2008","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R20-3-20210131","doi-asserted-by":"crossref","first-page":"662","DOI":"10.7326\/0003-4819-148-9-200805060-00006","article-title":"Narrative review: buprenorphine for opioid-dependent patients in office practice.","volume":"148","author":"Sullivan","year":"2008","journal-title":"Ann Intern Med"},{"key":"R21-3-20210131","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right.","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R22-3-20210131","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jsat.2006.11.009","article-title":"Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-related heroin-addicted patients.","volume":"33","author":"Maremmani","year":"2007","journal-title":"J Subst Abuse Treat"},{"key":"R23-3-20210131","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.","volume":"343","author":"Johnson","year":"2000","journal-title":"N Engl J Med"},{"key":"R24-3-20210131","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.","volume":"349","author":"Fudala","year":"2003","journal-title":"N Engl J Med"},{"key":"R25-3-20210131","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0376-8716(03)00059-0","article-title":"Clinical efficacy of buprenorphine: comparisons to methadone and placebo.","volume":"70","author":"Ling","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R26-3-20210131","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","article-title":"Buprenorphine retention in primary care.","volume":"20","author":"Stein","year":"2005","journal-title":"J Gen Intern Med"},{"key":"R27-3-20210131","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 1","key":"R28-3-20210131","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/QAI.0b013e318209740f","article-title":"A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care.","volume":"56","author":"Cheever","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R29-3-20210131","first-page":"S1","article-title":"Integration of buprenorphine\/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.","volume":"56","author":"Weiss","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R30-3-20210131","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/QAI.0b013e318209d3b9","article-title":"Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine\/naloxone and HIV care.","volume":"56","author":"Chaudhry","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R31-3-20210131","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/QAI.0b013e31820bc9a5","article-title":"Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine\/naloxone.","volume":"56","author":"Korthuis","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R32-3-20210131","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/QAI.0b013e31820a9a66","article-title":"The cost of integrated HIV care and buprenorphine\/naloxone treatment: results of a cross-site evaluation.","volume":"56","author":"Schackman","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R33-3-20210131","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/QAI.0b013e3182097537","article-title":"Drug treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone.","volume":"56","author":"Fiellin","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R34-3-20210131","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/QAI.0b013e3182097576","article-title":"The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine\/naloxone.","volume":"56","author":"Sullivan","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R35-3-20210131","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","article-title":"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study.","volume":"56","author":"Altice","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R36-3-20210131","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1097\/QAI.0b013e31820a820f","article-title":"Hepatic safety and lack of antiretroviral interactions with buprenorphine\/naloxone in HIV-infected opioid-dependent patients.","volume":"56","author":"Vergara-Rodriguez","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R37-3-20210131","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/QAI.0b013e3182097561","article-title":"Patient perspectives on buprenorphine\/naloxone treatment in the context of HIV care.","volume":"56","author":"Egan","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R38-3-20210131","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1097\/QAI.0b013e31820a9a97","article-title":"Policy implications of integrating buprenorphine\/naloxone treatment and HIV care.","volume":"56","author":"Finkelstein","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R39-3-20210131","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1097\/QAI.0b013e31820a9a82","article-title":"Opioid prescribing and provider confidence recognizing opioid abuse in HIV primary care settings.","volume":"56","author":"Lum","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R40-3-20210131","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","article-title":"Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment.","volume":"51","author":"Gandek","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"R41-3-20210131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","article-title":"An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.","volume":"168","author":"McLellan","year":"1980","journal-title":"J Nerv Ment Dis"},{"key":"R42-3-20210131","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment.","volume":"36","author":"Netherland","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"R43-3-20210131","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1017\/S0033291700048017","article-title":"The Brief Symptom Inventory: an introductory report.","volume":"13","author":"Derogatis","year":"1983","journal-title":"Psychol Med"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAI.0b013e3182097426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:04Z","timestamp":1786041904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201103011-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":43,"journal-issue":{"issue":"Supplement 1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3182097426","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,1]]}}}